Cellectis S.A.
NASDAQ:CLLSBiotechnology
-$0.02 today
- Market cap
- $103.75M
- Beta
- 2.75
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.67
Volume 0.01M
Average 0.04M
CLLS Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Cellectis S.A.NASDAQ: CLLS
Revenue · Q1 FY2026 · quarter ended Mar 2026
Revenue dips below year-ago levels
Q1 FY2026 revenue of $5.8M fell 45.6% year over year, behind the +42.9% change in trailing-twelve-month revenue. Sequentially, it fell 44.2% from the prior quarter. Over 3 fiscal years it compounded at +56.1% a year.
Context
- Revenue increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 3 analysts of $40.11M (-45.0%) for the fiscal year ending Dec 2026, a slowdown from the +75.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $5.8M-44.2% QoQ
- Last fiscal yearDec 2025
- $72.95M+75.8% YoY
- LTMMar 2026
- $68.09M+42.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -45.6% | -33.9% | +11.7 pp |
| 1 year | +75.8% | -45.0% | -120.8 pp |
| 3-year CAGR | +56.1% | -2.4% | -58.5 pp |
| 5-year CAGR | -19.3% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 72.95M USD
- Year-over-year change
- +75.8%
- 4-year CAGR
- +24.5%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 72.95M | +75.8% |
| FY2024 | 2024-12-31 | 41.51M | +5397.5% |
| FY2023 | 2023-12-31 | 755K | -96.1% |
| FY2022 | 2022-12-31 | 19.17M | -36.8% |
| FY2021 | 2021-12-31 | 30.35M | — |
Revenue vs competitors
How CLLS compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of +42.9% is the highest of 5, against a peer median of -53.6%.
- Over three fiscal years its annual growth of +56.1% compares with a peer median of -16.7%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | $214.88M USD | +0.3% | -16.7% | |
| LTM Mar 2026 | $68.09M USD | +42.9% | +56.1% | |
| LTM Mar 2026 | $3.84M USD | -20.3% | — | |
| LTM Mar 2026 | CHF 3.7M CHF | -86.9% | -3.2% | |
| LTM Mar 2026 | $921.49K USD | — | -68.4% | |
| LTM Mar 2026 | $500K USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| LTM Mar 2026 | $0 USD | -100.0% | — | |
| LTM Mar 2026 | $0 USD | — | — | |
| Peer median (excluding CLLS) | — | -53.6% | -16.7% | |
Competitors are the stored peer set for CLLS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 30.35M | 19.17M | 755K | 41.51M | 72.95M |
| Cost of Revenue | 1.84M | 8.48M | 7.42M | 9.18M | 9.8M |
| Gross Profit | 28.5M | 10.69M | (6.66M) | 32.32M | 63.15M |
| Gross Margin | 93.9% | 55.7% | -882.6% | 77.9% | 86.6% |
| Research & Development | 117.84M | 97.5M | 87.65M | 90.54M | 93.52M |
| Selling, General & Admin | 22.88M | 8.9M | 8.12M | 8.42M | 8.6M |
| Operating Expenses | 131.98M | 100.35M | 90.64M | 91.88M | 96.23M |
| Depreciation & Amortization | 14.16M | 18.44M | 18.52M | 19.85M | 20.06M |
| EBITDA | (78.43M) | (76.38M) | (92.64M) | (9.46M) | (39.85M) |
| EBITDA Margin | -258.4% | -398.4% | -12269.8% | -22.8% | -54.6% |
| Operating Income | (103.48M) | (89.67M) | (97.3M) | (59.55M) | (33.08M) |
| Operating Margin | -341.0% | -467.7% | -12887.7% | -143.5% | -45.3% |
| Interest Income | 719K | 1.12M | 3.61M | 11.28M | 9.5M |
| Interest Expense | 4.37M | 3.79M | 5.31M | 7.45M | 8.11M |
| Other Income / Expenses | 6.73M | (8.94M) | (19.16M) | 22.79M | (34.94M) |
| Income Before Tax | (96.75M) | (98.6M) | (116.46M) | (36.76M) | (68.02M) |
| Pre-Tax Margin | -318.8% | -514.3% | -15425.7% | -88.6% | -93.2% |
| Income Tax Expense | (3K) | 87K | 371K | 0 | (423K) |
| Net Income | (114.2M) | (106.14M) | (101.06M) | (36.76M) | (67.59M) |
| Net Margin | -376.3% | -553.6% | -13385.3% | -88.6% | -92.7% |
| EPS (Basic) | (1.93) | (2.33) | (1.77) | (0.41) | (0.68) |
| EPS (Diluted) | (1.93) | (2.33) | (1.77) | (0.41) | (0.68) |
| Weighted Avg Shares | 44.82M | 45.55M | 57.01M | 90.57M | 100.28M |
| Weighted Avg Shares (Diluted) | 44.82M | 45.55M | 57.01M | 90.57M | 100.28M |
Cellectis S.A.
NASDAQ:CLLS
Intrinsic Alpha fair value
Locked
Current Price
$1.03
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.